CD5-positive diffuse large B-cell lymphoma: A retrospective study in 337 patients treated by chemotherapy with or without rituximab

K. Miyazaki, M. Yamaguchi, R. Suzuki, Y. Kobayashi, A. M. Maeshima, N. Niitsu, D. Ennishi, J. I. Tamaru, K. Ishizawa, M. Kashimura, Y. Kagami, K. Sunami, H. Yamane, M. Nishikori, H. Kosugi, T. Yujiri, R. Hyo, N. Katayama, T. Kinoshita, S. Nakamura

Research output: Contribution to journalArticle

63 Citations (Scopus)

Abstract

Background: CD5-positive (CD5+) diffuse large B-cell lymphoma (DLBCL) shows poor prognosis and frequent central nervous system (CNS) relapses under anthracycline-containing chemotherapy. The aim of this study was to determine the prognosis and CNS relapse incidence of CD5+ DLBCL in the rituximab era. Patients and methods: We analyzed 337 patients with CD5+ DLBCL who received chemotherapy with (R-chemotherapy group; n = 184) or without (chemotherapy group; n = 153) rituximab. Results: No significant difference was found in clinical background comparisons between the two groups. In the R-chemotherapy group, 60% of the patients were older than 65 years at diagnosis. Both the complete response rate and overall survival (OS) were significantly better in the R-chemotherapy group (P = 0.0003 and P = 0.002, respectively). Multivariate analysis confirmed that chemotherapy without rituximab was associated with unfavorable OS. However, the probability of CNS relapse did not differ between the two groups (P = 0.89). The CNS relapse was strongly associated with short OS (P < 0.0001). In the R-chemotherapy group, 83% of patients who experienced CNS relapse had parenchymal disease. Conclusions: Our results indicate that rituximab improves the OS of patients with CD5+ DLBCL but does not decrease the CNS relapse rate. More effective treatments with CNS prophylaxis are needed for CD5+ DLBCL patients.

Original languageEnglish
Pages (from-to)1601-1607
Number of pages7
JournalAnnals of Oncology
Volume22
Issue number7
DOIs
Publication statusPublished - 2011

Keywords

  • CD5
  • Central nervous system
  • Diffuse large B-cell lymphoma
  • Prognosis
  • Rituximab

ASJC Scopus subject areas

  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'CD5-positive diffuse large B-cell lymphoma: A retrospective study in 337 patients treated by chemotherapy with or without rituximab'. Together they form a unique fingerprint.

  • Cite this

    Miyazaki, K., Yamaguchi, M., Suzuki, R., Kobayashi, Y., Maeshima, A. M., Niitsu, N., Ennishi, D., Tamaru, J. I., Ishizawa, K., Kashimura, M., Kagami, Y., Sunami, K., Yamane, H., Nishikori, M., Kosugi, H., Yujiri, T., Hyo, R., Katayama, N., Kinoshita, T., & Nakamura, S. (2011). CD5-positive diffuse large B-cell lymphoma: A retrospective study in 337 patients treated by chemotherapy with or without rituximab. Annals of Oncology, 22(7), 1601-1607. https://doi.org/10.1093/annonc/mdq627